Indicated as monotherapy for Grown ups with HR-positive, HER2-negative advanced or metastatic breast cancer with disorder progression following endocrine therapy and prior chemotherapy in metastatic placing 200 mg PO BID Abemaciclib targets CDK4 and CDK6, proteins that assist regulate mobile divi